

TRANSLATION/FOR REFERENCE PURPOSE ONLY

Securities code: 4536

June 25, 2008

**RESOLUTION NOTICE OF
THE 96TH ANNUAL GENERAL MEETING OF SHAREHOLDERS OF
SANTEN PHARMACEUTICAL CO., LTD.**

Dear Shareholder:

We hereby inform you of the reports and the resolutions that were made, as set forth below, in the 96th Annual General Meeting of Shareholders of the Corporation that was held today.

Reports:

1. Business Report, Consolidated Financial Statements and Financial Statements for the 96th Business Term (April 1, 2007 to March 31, 2008)
2. Independent Auditor Report and Corporate Auditor Report on the Consolidated Financial Statements for the 96th Business Term (April 1, 2007 to March 31, 2008)

As regards the items set forth above, the contents thereof were reported.

Resolved Items:

Proposal No.1: Appropriation of Surplus

This item was approved as per the original proposal. The term-end dividends of profits were resolved to be JPY 40 per share. Consequently, the total dividends for the annual business term, including the interim dividends are JPY 80 per share.

Proposal No.2: Appointment of Seven (7) Directors

As regards this item, Takakazu Morita, Akira Kurokawa, Masahiro Mita, Katsuhiro Waga, Isao Muramatsu, Noboru Kotani and Tatsuhiko Hamamoto were appointed as per the original proposal; each of them assumed their respective offices.

Isao Muramatsu, Noboru Kotani and Tatsuhiko Hamamoto are Outside Directors.

Proposal No.3: Appointment of One (1) Corporate Auditor

As regards this item, Yukinori Mizumoto was appointed as per the original proposal; he assumed his office.

Proposal No.4: Issuance of the Right to Subscribe for New Shares as Stock Options for the Directors

This item was approved as per the original proposal. It was resolved that the right to subscribe for new shares shall be issued to the Directors of the Corporation (except for Outside Directors), up to a maximum of 874 rights (87,400 shares).

TRANSLATION/FOR REFERENCE PURPOSE ONLY

Proposal No.5: Issuance of the Right to Subscribe for New Shares as Stock Options for the Corporate Officers

This item was approved as per the original proposal. It was resolved that the right to subscribe for new shares shall be issued to the Corporate Officers of the Corporation, up to a maximum of 743 rights (74,300 shares).

Yours very truly,

Akira Kurokawa
President & CEO
SANTEN PHARMACEUTICAL CO., LTD.
9-19, Shimoshinjo 3-chome, Higashiyodogawa-ku, Osaka, Japan

TRANSLATION/FOR REFERENCE PURPOSE ONLY

ANNOUNCEMENT

At the Board of Directors meeting, which was held after the close of this Annual General Meeting of Shareholders, Takakazu Morita was appointed as Representative Director and Chairman; Akira Kurokawa as Representative Director, President and Chief Executive Officer; and Masahiro Mita as Managing Director. Each of them assumed their respective offices. Furthermore, the Corporate Officers of the Corporation will assume their offices effective July 1, 2008.

Directors and Corporate Auditors

Takakazu Morita	Chairman
Akira Kurokawa	President and Chief Executive Officer
Masahiro Mita, M.D., Ph.D.	Managing Director Corporate and Regulatory Affairs
Katsuhiro Waga	Director Community and Environment Relations
Isao Muramatsu*	Director
Noboru Kotani*	Director
Tatsuhiko Hamamoto*	Director
Yukinori Mizumoto	Standing Corporate Auditor
Tadao Kagono**	Corporate Auditor
Yasuo Sato**	Corporate Auditor
Eiju Miyauchi**	Corporate Auditor

* Outside Director

**External Corporate Auditor

TRANSLATION/FOR REFERENCE PURPOSE ONLY

Corporate Officers (excluding Corporate Officers who are also Members of the Board)

Toshiaki Nishihata, Ph.D.	Senior Corporate Officer Head of Research and Development Division
Sadatoshi Furukado	Senior Corporate Officer Head of Sales and Marketing Division, Prescription Pharmaceuticals
Kenji Iwamoto	Corporate Officer Head of Asia Division
Masamichi Sato	Corporate Officer Corporate Planning/Strategic HR/OTC Business
Adrienne Graves, Ph.D.	Corporate Officer President of Santen Inc.
Jyrki Liljeroos	Corporate Officer President of Santen Oy
Kenji Morishima	Corporate Officer Head of Product Supply Division
Yoshihiro Noutsuka	Corporate Officer Head of Planning and Control Division

End.